Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
Saturday, October 9, 2010 - 05:01
in Health & Medicine
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.